Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Achieve Life Sciences amends technology license agreement with University of Bristol

Jan. 25, 2018

AP-202 shows promise as an agent for nicotine addiction

Jan. 23, 2018

FDA issues complete response letter for CAM-2038 NDA for opioid use disorder

Jan. 22, 2018

Mosedipimod receives FDA orphan drug designation for ARS

Jan. 5, 2018

Addex and Indivior sign licensing and collaboration agreement for ADX-71441 to treat addiction

Jan. 3, 2018

Axsome Therapeutics and Duke University to collaborate on phase II study of AXS-05

Dec. 15, 2017

FDA approves once-monthly Sublocade to treat opioid use disorder

Dec. 1, 2017

FDA accepts, grants priority review to lofexidine NDA

Nov. 22, 2017

Orexo's Zubsolv approved for opioid dependence in Europe

Nov. 21, 2017

OX1 receptor antagonist C4X_3256 demonstrates efficacy in nicotine dependence rat model

Nov. 15, 2017

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...